BRAF V600E is now actionable in metastatic colorectal cancer

contact an expert

Specific results your oncologists can trust

Up to 15% of colorectal cancer cases have mutations in the BRAF gene (1) and of those mutations, V600E accounts for over 99% (2). 

The therascreen BRAF V600E RGQ PCR Kit is an FDA-approved companion diagnostic (CDx) test to identify patients with cases of metastatic colorectal cancer (mCRC) that harbor the V600E mutation in the BRAF gene, and for whom treatment with BRAFTOVI (encorafenib) + cetuximab may be appropriate. The test uses DNA extracted from formalin-fixed, paraffin-embedded (FFPE) human colorectal cancer (CRC) tumor tissue.

learn about the test

The tools you need to ensure patients receive the best individualized care

QIAGEN’s therascreen kits allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

  1. Corcoran, R.B., Ebi, H., Turke, A.B., et al. (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227.
  2. COSMIC, the Catalogue Of Somatic Mutations In Cancer. GRCh38/cosmic/v89/.